Evidence map›Paper›PMID 41891089›Full record

ReviewInternational journal of transgender health2026

Prostatic diseases in transgender women: A systematic review of diagnosis, risk, and management.

Alice Bourillon, Cyrille Guillot-Tantay, Lucas Freton, Lee Zhao, Benoit Mesnard, Nicolas Morel-Journel, Romain Mathieu, Paul Neuville, Aurélie Schirmann, Benoit Peyronnet and 1 more

Abstract readReview
In one paragraph

Review in International journal of transgender health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alice BourillonDepartment of Urology, University of Rennes, Rennes, France.ORCID https://orcid.org/0009-0007-8712-5752
Cyrille Guillot-TantayDepartment of Urology, Foch Hospital, Suresnes, France.ORCID https://orcid.org/0000-0002-3948-7544
Lucas FretonDepartment of Urology, University of Rennes, Rennes, France.ORCID https://orcid.org/0000-0001-5624-1952
Lee ZhaoDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-4029-0669
Benoit MesnardDepartment of Urology, Nantes University Hospital, Nantes, France.ORCID https://orcid.org/0000-0002-3314-1892
Nicolas Morel-JournelDepartment of Urology, Hospices Civils de Lyon, Lyon, France.
Romain MathieuDepartment of Urology, University of Rennes, Rennes, France.ORCID https://orcid.org/0000-0002-6866-7827
Paul NeuvilleDepartment of Urology, Hospices Civils de Lyon, Lyon, France.ORCID https://orcid.org/0000-0002-0241-021X
Aurélie SchirmannDepartment of Urology, Foch Hospital, Suresnes, France.
Benoit PeyronnetDepartment of Urology, University of Rennes, Rennes, France.
François-Xavier MadecDepartment of Urology, Foch Hospital, Suresnes, France.ORCID https://orcid.org/0000-0002-5577-341X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Most transgender women have their prostate left in situ throughout and after their transition. Managing prostate‑related conditions in transgender women remains challenging due to the lack of clear recommendations. This review aims to summarize the available data on prostate health, including cancer screening and treatment, lower urinary tract symptoms, and prostate evaluation. Material and methods: A comprehensive literature review was conducted in accordance with the PRISMA statement using PubMed, Embase, and The Cochrane Library, with the keywords (prostate), (lower urinary tract symptoms (LUTS)), (prostate evaluation), and (transgender women). All relevant data were analyzed. Results: Twenty studies were included in the final analysis: 15 focused on prostate cancer, four on LUTS, and one on prostate evaluation. A total of 961 prostate cancer cases were identified. Of the 17 detailed oncologic treatments, the most common were surgery and hormone therapy. Data regarding LUTS and prostate evaluation were very limited; the most frequently reported symptom was a split urinary stream. Surgical interventions for LUTS included two cases of transurethral resection of the prostate (TURP) and one Rezum procedure. Prostate evaluation was performed via transvaginal exam in 50 patients. Transvaginal ultrasonographic assessment of the prostate was feasible in 67 out of 70 patients (96%). Conclusion: The present systematic review demonstrates that prostatic diseases can occur in transgender women. Neovaginal prostatic exam appears as the appropriate way to assess the prostate on physical exam. The paucity of data highlights the need to raise awareness of healthcare professionals and to promote further research on this critical issue.

Indexed as

Lower urinary tract symptomsProstateProstatic NeoplasmsTransgenderismTransgender women

Identifiers

PMID41891089
PMCPMC13015100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.